In this week\u2019s Psychedelic Policy Briefing, investigative journalist Jack Gorsline digs into the details of developments that could impact research into psychedelic-assisted therapies including multi-site VA clinical trials.\u2026", "outcome_summary": "The VA launched PIVOT, a five-site clinical trial evaluating the therapeutic use of psilocybin for veterans with treatment-resistant depression. The trial investigates COMP360, a patented synthetic form of psilocybin, and aims to establish safety parameters and dosing protocols.", "doi": null, "url": "https://www.lucid.news/weekly-psychedelic-policy-briefing-august-14-2026/", "source": "Lucid News", "first_seen": "2026-08-24", "relevance": { "relevant": true, "reason": "Psilocybin for treatment-resistant depression in veterans.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-24" } }, { "id": "a402b35b21b2d6b4b03e55054c2a2c56f7f3d4601b3e8d60cafa2666b6435fc7", "title": "Compass Pathways Announces Six-Month Data from Second Phase 3 Trial Confirming Rapid and Durable Profile", "compound": "psilocybin", "type": "phase_3", "institution": "Compass Pathways plc", "condition": "depression", "sample_size": 600, "status": "active", "date": "2026-07-07", "abstract": "These risks, uncertainties, and other factors include, among others: uncertainties associated with risks related to clinical development which is a lengthy and expensive process with uncertain outcomes, and therefore our clinical trials may be delayed or terminated and may be more costly than expected; the full results and safety data from our Phase 3 clinical trials in TRD may not be consistent with the preliminary results to date; our need for substantial additional funding to achieve our [...] of more than 3 years on average and a history of over 6 lifetime episodes.\u2026", "outcome_summary": "The second Phase 3 trial (COMP006) for COMP360 (psilocybin) in treatment-resistant depression showed that 39% of participants in the 25 mg arm achieved a clinically meaningful reduction in depression symptoms by week 6, maintaining this response through week 26. The drug demonstrated a rapid onset and durable profile with a generally well-tolerated safety profile.", "doi": null, "url": "https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-Announces-Six-Month-Data-from-Second-Phase-3-Trial-Confirming-Rapid-and-Durable-Profile", "source": "Compass Pathways", "first_seen": "2026-08-24", "relevance": { "relevant": true, "reason": "Phase 3 trial of psilocybin for treatment-resistant depression.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-24" } }, { "id": "9ca55c254db8172eec3a6e2f2191b4ee7dd1868da614af6110560fc77991913b", "title": "COMPASS Pathways launches phase II clinical trial of psilocybin therapy in anorexia nervosa", "compound": "psilocybin", "type": "phase_2", "institution": "COMPASS Pathways plc", "condition": "eating_disorder", "sample_size": 60, "status": "recruiting", "date": "2022-07-28", "abstract": "and which could cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. [...] support.\u2026", "outcome_summary": "A multi-centre, double-blind randomised controlled phase II trial will investigate the efficacy of COMP360 psilocybin therapy in anorexia nervosa. The trial will compare 25 mg and 1 mg of COMP360 psilocybin in 60 participants, with the primary endpoint being the change from baseline in the EDE global score at week 4.", "doi": null, "url": "https://ir.compasspathways.com/News--Events-/news/news-details/2022/COMPASS-Pathways-launches-phase-II-clinical-trial-of-psilocybin-therapy-in-anorexia-nervosa/default.aspx", "source": "Compass Pathways", "first_seen": "2026-08-24", "relevance": { "relevant": true, "reason": "Psilocybin therapy for anorexia nervosa, a psychiatric indication.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-24" } }, { "id": "716bb4ce69324dff0a146ca52d94f2a7041eab71a8e134d6347a1c39b6e1f79a", "title": "Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD", "compound": "psilocybin", "type": "phase_3", "institution": "Compass Pathways plc", "condition": "PTSD", "sample_size": null, "status": "recruiting", "date": "2026-01-07", "abstract": "These risks, uncertainties, and other factors include, among others: uncertainties associated with risks related to clinical development which is a lengthy and expensive process with uncertain outcomes, and therefore our clinical trials may be delayed or terminated and may be more costly than expected; the results of early-stage clinical trials of our investigational COMP360 psilocybin treatment may not be predictive of the results of later stage clinical trials; our need for substantial [...] and goals; our expectations and projections about the company\u2019s future cash needs and financial results; our plans and expectations regarding our clinical trials, including our phase 3 trials in TRD and our planned phase 2b/3 trial in PTSD, our expectations regarding the time periods for the release of data from the COMP005 and COMP006 Phase 3 trials for TRD; our expectations regarding discussions with the FDA, including discussions regarding potential NDA acceleration strategies, including [...] Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that the U.S.\u2026", "outcome_summary": "The FDA has accepted Compass Pathways' IND application for COMP360, allowing for the initiation of a late-stage clinical trial in patients with PTSD. The company is also advancing commercialization plans for treatment-resistant depression (TRD).", "doi": null, "url": "https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-Announces-FDA-Acceptance-of-IND-Application-for-PTSD-and-Hosts-Webinar-on-PTSD-and-TRD/default.aspx", "source": "Compass Pathways", "first_seen": "2026-08-24", "relevance": { "relevant": true, "reason": "IND acceptance for PTSD and TRD clinical trials", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-24" } }, { "id": "61869b1f739ca68c7cbc95e6beb7d8704d5f9a45d64fc933ac29309da4d7bc7f", "title": "COMPASS Pathways announces publication of phase 2b study of COMP360 psilocybin therapy for treatment-resistant depression in The New England Journal of Medicine", "compound": "psilocybin", "type": "phase_2", "institution": "COMPASS Pathways", "condition": "depression", "sample_size": 233, "status": "published", "date": "2022-11-03", "abstract": "About the COMP360 psilocybin therapy phase 2b study This randomised, controlled, multicentre, double-blind phase 2b trial is the largest psilocybin therapy clinical trial ever conducted, with 233 patients from 10 countries in North America and Europe.\u2026", "outcome_summary": "A single 25mg dose of COMP360 psilocybin therapy, combined with psychological support, resulted in remission for approximately 30% of patients with treatment-resistant depression by week 3, with sustained response observed through week 12. The 25mg dose showed a greater impact on depression symptoms compared to lower doses.", "doi": null, "url": "https://ir.compasspathways.com/News--Events-/news/news-details/2022/COMPASS-Pathways-announces-publication-of-phase-2b-study-of-COMP360-psilocybin-therapy-for-treatment-resistant-depression-in-The-New-England-Journal-of-Medicine/default.aspx", "source": "Compass Pathways", "first_seen": "2026-08-24", "relevance": { "relevant": true, "reason": "Phase 2b study of psilocybin therapy for treatment-resistant depression.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-24" } }, { "id": "2ac87fc5b84858304a229371b1055d3bb2b8fbef7c5a9f7f3901943f746ceed0", "title": "Psilocybin Safe And Effective Against Mood Disorders, Real-World Data Show", "compound": "psilocybin", "type": "observational", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-08-18", "abstract": "For the new study, researchers evaluated nearly 350 people receiving psychiatric care at 24 of Oregon\u2019s 26 licensed psilocybin service centers. The participants all received a single session with the psychedelic drug between November 2024 and June 2026, under the care of a licensed facilitator.\u2026", "outcome_summary": "Real-world data indicates that psilocybin is safe and effective in treating mood disorders.", "doi": null, "url": "https://www.usnews.com/news/health-news/articles/2026-08-21/psilocybin-safe-and-effective-against-mood-disorders-real-world-data-show", "source": "General News", "first_seen": "2026-08-24", "relevance": { "relevant": true, "reason": "Psilocybin for mood disorders, real-world data.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-24" } }, { "id": "148c83ab07288d27a4b43c7730623e1d18de606ec83ad3806a3af905c09d66b8", "title": "Study finds sustained benefit for people using Oregon psilocybin services", "compound": "psilocybin", "type": "observational", "institution": "Oregon Health & Science University", "condition": "other", "sample_size": null, "status": "published", "date": "2026-08-20", "abstract": "# News Text Size A A A Share twitter Tweet Share Email Print # Study finds sustained benefit for people using Oregon psilocybin services OHSU-led research is the largest study of psychedelics outside clinical trials By Erik Robinson August 19, 2026 Portland, Oregon A psilocybin mushroom rests on a glass slide in a laboratory.\u2026", "outcome_summary": "Participants in a study of Oregon psilocybin services reported relief from symptoms of anxiety, depression, and PTSD, with almost two-thirds declaring the experience to be among the most meaningful of their life. Safety was similar to clinical settings, with few adverse events reported.", "doi": "10.1001/jamanetworkopen.2026.3028", "url": "https://news.ohsu.edu/2026/08/19/study-finds-sustained-benefit-for-people-using-oregon-psilocybin-services", "source": "General News", "first_seen": "2026-08-24", "relevance": { "relevant": true, "reason": "Human study on psilocybin for anxiety, depression, and PTSD.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-24" } }, { "id": "7590c3279e76c8020be8c7a0823bd6997f3239f196fc025de55c727b22d0e788", "title": "Psilocybin users report real-world outcomes in new study", "compound": "psilocybin", "type": "observational", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-08-21", "abstract": "Scott M. Thompson et al, Real-world use, safety, and mental health efficacy of regulated psilocybin services in Oregon and Colorado, medRxiv (2026). DOI: 10.64898/2026.08.11.26360133.\u2026", "outcome_summary": "A study published in the Journal of Psychopharmacology found that individuals who used psilocybin for mental health purposes reported positive outcomes, including reduced symptoms of depression and anxiety, and improved overall well-being. The study surveyed 1,169 psilocybin users, with the majority reporting significant benefits.", "doi": null, "url": "https://medicalxpress.com/news/2026-08-psilocybin-users-real-world-outcomes.html", "source": "General News", "first_seen": "2026-08-24", "relevance": { "relevant": true, "reason": "Naturalistic study of psilocybin for mental health outcomes.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-24" } }, { "id": "16d35e5b525a1a33beb227c9ef04db5f638e31c6d6635e419299e3bf3466e63a", "title": "More than 20,000 people have used legal psilocybin in Oregon. A new study shows how it went", "compound": "psilocybin", "type": "observational", "institution": "OHSU", "condition": "depression", "sample_size": 350, "status": "published", "date": "2026-08-19", "abstract": "### Health # More than 20,000 people have used legal psilocybin in Oregon. A new study shows how it went By Amelia Templeton (OPB) Aug. 19, 2026 11:01 p.m. ## OHSU lead researcher Todd Korthuis spoke with OPB about the first rigorous study of legal psilocybin used in the state.\u2026", "outcome_summary": "A study of 350 volunteers in Oregon's legal psilocybin program found that a majority reported fewer symptoms of anxiety and depression, and serious negative mental health impacts occurred in only about 1% of participants. The program's safety was assessed as comparable to clinical trials despite a less controlled environment.", "doi": "https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2853028", "url": "https://www.opb.org/article/2026/08/19/psilocybin-oregon-use-ohsu-study-results", "source": "General News", "first_seen": "2026-08-24", "relevance": { "relevant": true, "reason": "Study on legal psilocybin program for mental health", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-24" } } ], "mdma": [ { "id": "5e2f6fa1060fe8754f3a2108a048a33a5b6485da1af1f1f5143c1f39b587eeeb", "title": "Aesthetic mediation and lateral agency: Rethinking trauma and drug consumption in 'crisis ordinariness'.", "compound": "mdma", "type": "phase_2", "institution": null, "condition": "other", "sample_size": null, "status": "published", "date": "2026-08-21", "abstract": "Trauma has a become a dominant causal explanation in psychological and public health accounts of drug use, with drug consumption typically framed as a coping response or form of self-medication.\u2026", "outcome_summary": null, "doi": "10.1016/j.drugpo.2026.105471", "url": "https://pubmed.ncbi.nlm.nih.gov/42628311/", "source": "PubMed", "first_seen": "2026-08-24", "relevance": { "relevant": true, "reason": "Discusses trauma and drug consumption as a coping mechanism.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-24" } }, { "id": "e0c3ffdce6c5b9a950d310b5995f0adb032284f3e23dba8b6e582aff255ac425", "title": "From Molecules to Minds: Redefining the Power of Psychedelics and Entactogens in Treating Brain Disorders.", "compound": "mdma", "type": "phase_2", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-07-31", "abstract": "Recent advances in neuropsychopharmacology have renewed interest in psychedelics and entactogens as potential treatments for brain disorders, owing to their rapid effects on neural plasticity, cognition, and affect.\u2026", "outcome_summary": null, "doi": "10.2174/0118715273452468260729080541", "url": "https://pubmed.ncbi.nlm.nih.gov/42613695/", "source": "PubMed", "first_seen": "2026-08-24", "relevance": { "relevant": true, "reason": "Psychedelics for brain disorders, including neural plasticity and affect.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-24" } } ], "ketamine": [ { "id": "7cd6bfe744509d95819423b53de933b0ec8362fe72209999408ece6c5bc13637", "title": "Ketamine Safety and Therapeutic Opportunity in Late-Life Depression With Depression-Executive Dysfunction Syndrome (DED).", "compound": "ketamine", "type": "phase_2", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-07-30", "abstract": null, "outcome_summary": null, "doi": "10.1016/j.jagp.2026.07.014", "url": "https://pubmed.ncbi.nlm.nih.gov/42632766/", "source": "PubMed", "first_seen": "2026-08-24", "relevance": { "relevant": true, "reason": "Ketamine for late-life depression and executive dysfunction.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-24" } }, { "id": "668342cf2b51f9721520a5a7aa545916f1d52158d6f278f149b7afb8d351c575", "title": "Depression Heterogeneity as a Confounder in Ketamine Response for Late-Life Depression.", "compound": "ketamine", "type": "phase_2", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-07-29", "abstract": null, "outcome_summary": null, "doi": "10.1016/j.jagp.2026.07.015", "url": "https://pubmed.ncbi.nlm.nih.gov/42632765/", "source": "PubMed", "first_seen": "2026-08-24", "relevance": { "relevant": true, "reason": "Ketamine for late-life depression in humans.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-24" } }, { "id": "480e7f8735d5ec7aa5f2f3a942e3c698ef6fb3c17ba7e9d04b4b532fd5d49521", "title": "Single-Infusion Ketamine in Older Adults With Depression and Mild Cognitive Impairment: Promising Signal, Falls, and Cognitive Safety Need Closer Scrutiny.", "compound": "ketamine", "type": "phase_2", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-07-30", "abstract": null, "outcome_summary": null, "doi": "10.1016/j.jagp.2026.07.012", "url": "https://pubmed.ncbi.nlm.nih.gov/42632764/", "source": "PubMed", "first_seen": "2026-08-24", "relevance": { "relevant": true, "reason": "Ketamine for depression and cognitive impairment in older adults.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-24" } }, { "id": "585f1ae688eb232f2af06601026551409685847264d642675b6037fd6b583fac", "title": "Comment on \"KET-MCI: A Pilot Safety and Tolerability Study of Single Infusion Intravenous Ketamine for Older Adults With Depression and Mild Cognitive Impairment\".", "compound": "ketamine", "type": "phase_2", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-07-30", "abstract": null, "outcome_summary": null, "doi": "10.1016/j.jagp.2026.07.013", "url": "https://pubmed.ncbi.nlm.nih.gov/42629230/", "source": "PubMed", "first_seen": "2026-08-24", "relevance": { "relevant": true, "reason": "Ketamine for depression and mild cognitive impairment in older adults.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-24" } }, { "id": "fb3cf057efb5c2da9736828a5f81d2f19d68c4f86860a2a5b841f756a9ebcd00", "title": "A scoping review: ketamine or esketamine when used to assist psychotherapy or in combination with psychotherapy for the management of depression in adults.", "compound": "ketamine", "type": "phase_2", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-07-27", "abstract": "This scoping review maps literature for use of ketamine or esketamine with psychotherapy for depression or depressive symptoms.\u2026", "outcome_summary": null, "doi": "10.1038/s44184-026-00226-1", "url": "https://pubmed.ncbi.nlm.nih.gov/42624888/", "source": "PubMed", "first_seen": "2026-08-24", "relevance": { "relevant": true, "reason": "Ketamine/esketamine for depression with psychotherapy.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-24" } }, { "id": "5dd31960be9964c4b1289cf8ec6c0a40b218c88d2fde0051d554063551b5a84f", "title": "Suicidal ideation covaries with depressive severity during six-month real-world esketamine treatment in a cohort enriched for borderline personality disorder.", "compound": "ketamine", "type": "phase_2", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-08-20", "abstract": null, "outcome_summary": null, "doi": "10.1016/j.jad.2026.122405", "url": "https://pubmed.ncbi.nlm.nih.gov/42624219/", "source": "PubMed", "first_seen": "2026-08-24", "relevance": { "relevant": true, "reason": "Esketamine for suicidal ideation and depression in humans.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-24" } }, { "id": "0c110b576465913f8f0f7822d3f048988f065014565f17bae14d2b60c6d6f063", "title": "Integrating Ketamine and Autogenic Training for Chronic Pain: A Case Study at Walter Reed National Military Medical Center.", "compound": "ketamine", "type": "phase_2", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-08-20", "abstract": "Ketamine has demonstrated efficacy in managing chronic pain and, when combined with psychotherapy, alleviating psychiatric symptoms. However, no published studies have examined the integration of ketamine infusion with autogenic training for chronic pain management.\u2026", "outcome_summary": null, "doi": "10.1093/milmed/usag396", "url": "https://pubmed.ncbi.nlm.nih.gov/42623656/", "source": "PubMed", "first_seen": "2026-08-24", "relevance": { "relevant": true, "reason": "Ketamine for chronic pain in humans, case study.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-24" } }, { "id": "9a7e2c316d3c3453b7044fb92b22bf14ff48ef63ec3dddbfc90893cb6fdb5f3d", "title": "Ultrasonic potentiation of ketamine neuromodulation.", "compound": "ketamine", "type": "phase_2", "institution": null, "condition": "other", "sample_size": null, "status": "published", "date": "2026-08-04", "abstract": "The psychiatric utility of ketamine is limited by its dissociative and systemic side effects.\u2026", "outcome_summary": null, "doi": "10.64898/2026.07.29.741494", "url": "https://pubmed.ncbi.nlm.nih.gov/42620088/", "source": "PubMed", "first_seen": "2026-08-24", "relevance": { "relevant": true, "reason": "psychiatric utility of ketamine", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-24" } }, { "id": "59bf918f1a32a8487f4dd26bf5aa983f9f1964324b03218dccc0f8067912ce6a", "title": "Ketamine infusion as an adjunct therapy to aid opioid rotation to buprenorphine: A case series.", "compound": "ketamine", "type": "phase_2", "institution": null, "condition": "addiction", "sample_size": null, "status": "published", "date": "2026-05-01", "abstract": "There are increasing rates of opioid prescriptions for chronic pain worldwide. Long-term opioid use for chronic noncancer pain is reported to be associated with problematic use and dependence.\u2026", "outcome_summary": null, "doi": "10.5055/jom.0937", "url": "https://pubmed.ncbi.nlm.nih.gov/42615303/", "source": "PubMed", "first_seen": "2026-08-24", "relevance": { "relevant": true, "reason": "Ketamine adjunct to opioid rotation for chronic pain.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-24" } }, { "id": "370bc53f01d0ff9b58c4dfcf60773e60b23f00da03b7635bdd08e2d6c7178e7e", "title": "Therapeutic Potential of Ketamine in Major Depressive Disorder: Pharmacological Insights and Clinical Evidence.", "compound": "ketamine", "type": "phase_2", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-07-31", "abstract": "Major depressive disorder (MDD) is one of the leading causes of disability globally, and conventional monoaminergic antidepressants often have a slow onset and limited efficacy.\u2026", "outcome_summary": null, "doi": "10.2174/0113816128462317260721102058", "url": "https://pubmed.ncbi.nlm.nih.gov/42613710/", "source": "PubMed", "first_seen": "2026-08-24", "relevance": { "relevant": true, "reason": "Ketamine for major depressive disorder (MDD) is a psychiatric indication.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-24" } }, { "id": "e57e7c4635291344c2bf0305d1ad7f3682ce2b0474cfafca33193230662b1d60", "title": "Ketamine's impact on rumination-related brain dynamics: insights from a randomized controlled fMRI trial.", "compound": "ketamine", "type": "phase_2", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-08-18", "abstract": "Rumination has been associated with aberrant dynamics of a coactivation pattern (CAP) comprising the default mode (DMN) and frontoparietal (FPN) networks. Ketamine exerts rapid antidepressant effects and may influence these dynamics via glutamatergic mechanisms.\u2026", "outcome_summary": null, "doi": "10.1038/s41398-026-04392-w", "url": "https://pubmed.ncbi.nlm.nih.gov/42613319/", "source": "PubMed", "first_seen": "2026-08-24", "relevance": { "relevant": true, "reason": "Ketamine for depression, human fMRI study.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-24" } }, { "id": "6c9b2eca9b95da7e275a728d51a1ecac946f66460b0785c01fc2a7942962eb6f", "title": "A Systematic Review of Long-term Safety Outcomes of Ketamine and Esketamine in Patients with Treatment-resistant Depression.", "compound": "ketamine", "type": "meta_analysis", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-08-17", "abstract": "Approximately 30-40% of patients with major depressive disorder fail to respond to conventional antidepressants. Ketamine and esketamine are increasingly used, yet synthesized data on cumulative safety remain limited. This systematic review evaluated long-term safety of both agents.\u2026", "outcome_summary": null, "doi": "10.1159/pps/aemag005", "url": "https://pubmed.ncbi.nlm.nih.gov/42611840/", "source": "PubMed", "first_seen": "2026-08-24", "relevance": { "relevant": true, "reason": "Long-term safety of ketamine/esketamine for treatment-resistant depression.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-24" } }, { "id": "aaf4d38c8356b39f7899580a194ff8820ed9fbb33f3b3eebec606a0bf6e7fd22", "title": "Profiling intranasal esketamine for adults with major depressive disorder and acute suicidal ideation or behavior: a phenotype-informed drug profile.", "compound": "ketamine", "type": "meta_analysis", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-08-18", "abstract": "Acute suicidal ideation in major depressive disorder (MDD) is a psychiatric emergency requiring rapid risk assessment, containment, and treatment. Conventional monoaminergic antidepressants have delayed onset, leaving an interval during which severe depressive distress persists.\u2026", "outcome_summary": null, "doi": "10.1080/14737175.2026.2714839", "url": "https://pubmed.ncbi.nlm.nih.gov/42610482/", "source": "PubMed", "first_seen": "2026-08-24", "relevance": { "relevant": true, "reason": "Esketamine for major depressive disorder and suicidal ideation.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-24" } }, { "id": "41043f52b3b71c02090c5553fe96f02c288fd5813ead95bb18c3e7137cbd6644", "title": "[(Es)ketamine: practice update].", "compound": "ketamine", "type": "phase_2", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-08-17", "abstract": "Ketamine has been established as an anesthetic agent for decades. Around the turn of the millennium initial clinical studies demonstrated that subanesthetic doses of ketamine can exert antidepressant effects in treatment-resistant depression.\u2026", "outcome_summary": null, "doi": "10.1007/s00115-026-02001-1", "url": "https://pubmed.ncbi.nlm.nih.gov/42606558/", "source": "PubMed", "first_seen": "2026-08-24", "relevance": { "relevant": true, "reason": "Antidepressant effects of subanesthetic ketamine doses.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-24" } }, { "id": "5567cb1c83065e8bc00b3c1b60e910e9671e11cdb6f751bac24bbb4a87d141ee", "title": "Exploratory non-randomized clinical trial of subcutaneous esketamine in treatment-resistant depression: Effects of ketamine-assisted psychotherapy.", "compound": "ketamine", "type": "phase_2", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-08-10", "abstract": "Ketamine is an effective rapid-acting treatment for treatment-resistant depression (TRD), producing antidepressant effects within hours of administration. Because it induces states of heightened neuroplasticity and psychological openness, psychotherapy may enhance its therapeutic effects.\u2026", "outcome_summary": null, "doi": "10.1016/j.jad.2026.122369", "url": "https://pubmed.ncbi.nlm.nih.gov/42575192/", "source": "PubMed", "first_seen": "2026-08-24", "relevance": { "relevant": true, "reason": "Esketamine for treatment-resistant depression in humans.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-24" } }, { "id": "bf612cebe8f5026e802ad50391da02effb54d2477f852856f465458d4a7e64ea", "title": "A Study of Esketamine Nasal Spray Versus Placebo Spray in Adult Participants With Treatment-resistant Depression", "compound": "ketamine", "type": "phase_3", "institution": "Janssen Research & Development, LLC", "condition": "depression", "sample_size": 348, "status": "recruiting", "date": "2026-07-27", "abstract": "The purpose of this study is to evaluate how well each individual dose of esketamine (56 milligrams \\[mg\\] and 84 mg) works when compared with placebo in improving depressive symptoms in participants with treatment resistant depression (individuals with major depressive disorder \\[MDD\\] who have not responded to at least 2 different antidepressant treatments given at an adequate dose for an adequate duration in the current episode of depression).", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT07716098", "source": "ClinicalTrials.gov", "first_seen": "2026-08-24", "relevance": { "relevant": true, "reason": "Esketamine for treatment-resistant depression in humans.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-24" } }, { "id": "4a925cb44a24a308b72990d2f0c6dac61765d2b3b40a8621e4e94bbc7a350e80", "title": "The Effect of Ketamine on Aesthetics and Role for Antidepressant Effects", "compound": "ketamine", "type": "phase_1", "institution": "Medical University of Vienna", "condition": "depression", "sample_size": 60, "status": "active", "date": "2022-06-01", "abstract": "The aim of this study is to assess the impact of ketamine on aesthetic perception and processing. This study assesses the role of these effects in facilitating ketamine's antidepressant properties, with a focus on anhedonia.\u2026", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT05320107", "source": "ClinicalTrials.gov", "first_seen": "2026-08-24", "relevance": { "relevant": true, "reason": "Ketamine's antidepressant effects and impact on aesthetic perception.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-24" } }, { "id": "24f1af7ea3e3deaa276ecc3885d4b2e55cbb24bf02b53fab2badb04d1adfcb9c", "title": "Ketamine in the Treatment of Depression", "compound": "ketamine", "type": "phase_2", "institution": "Columbia University", "condition": "depression", "sample_size": 38, "status": "completed", "date": "2012-02-01", "abstract": "Depressed patients will be offered experimental treatment with a new, potentially fast-acting antidepressant called ketamine while being scanned by magnetic resonance imaging (MRI) to measure the chemical effect of the drug.\u2026", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT01558063", "source": "ClinicalTrials.gov", "first_seen": "2026-08-24", "relevance": { "relevant": true, "reason": "Ketamine for depression treatment in humans.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-24" } }, { "id": "a61e931a4ef154861c1b68a6d93d3ceb1f9cd10cfb1fec12a2836d951392868b", "title": "Treatment Resistant Depression (Pilot)", "compound": "ketamine", "type": "observational", "institution": "Washington University School of Medicine", "condition": "depression", "sample_size": 20, "status": "completed", "date": "2012-04-01", "abstract": "Treatment resistant depression (TRD) is a major public health problem. Current therapeutic options for this patient population remain limited. With all available treatments, only a sub-set of those patients who achieve an antidepressant response are likely to achieve treatment-induced remission.\u2026", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT01179009", "source": "ClinicalTrials.gov", "first_seen": "2026-08-24", "relevance": { "relevant": true, "reason": "Treatment resistant depression is a psychiatric indication.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-24" } }, { "id": "5177c9ee962eb7919f262e77377b6e48c726f883514e2fadce45a1a864e1f792", "title": "A Study to Evaluate Central Nervous System (CNS) Pharmacodynamic Activity of TAK-653 in Healthy Participants Using Transcranial Magnetic Stimulation (TMS)", "compound": "ketamine", "type": "phase_1", "institution": "Neurocrine Biosciences", "condition": "other", "sample_size": 24, "status": "completed", "date": "2019-02-11", "abstract": "The primary purpose of this study is to determine whether TAK-653, in comparison to placebo, increases CNS excitability, assessed with TMS-evoked motor-evoked potential (MEP) in healthy participants.", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT03792672", "source": "ClinicalTrials.gov", "first_seen": "2026-08-24", "relevance": { "relevant": true, "reason": "Human study on CNS pharmacodynamic activity of a compound.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-24" } }, { "id": "de17685f6fc6e249ec74c2f9b3d2942ae7dd5e706c76a2ed17a568d368c960b1", "title": "A Study of CLE-100 (Oral Esketamine) in Addition to Standard Antidepressant Drug for Major Depressive Disorder - CLEO Study", "compound": "ketamine", "type": "phase_2", "institution": "Clexio Biosciences Ltd.", "condition": "depression", "sample_size": 146, "status": "completed", "date": "2019-09-05", "abstract": "The clinical trial is a Phase 2, double-blind, randomized, placebo controlled study in Major Depressive Disorder (MDD) participants currently treated with antidepressant therapy.\u2026", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT04103892", "source": "ClinicalTrials.gov", "first_seen": "2026-08-24", "relevance": { "relevant": true, "reason": "Esketamine for major depressive disorder in a human clinical trial.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-24" } }, { "id": "addc37e3e596921a410786306d3d0e87d55a9d9adf9a79864fb7fe0f460dfcab", "title": "Chart Review of Patients Undergoing Ketamine Treatments for Depression", "compound": "ketamine", "type": "observational", "institution": "Sunnybrook Health Sciences Centre", "condition": "depression", "sample_size": 250, "status": "completed", "date": "2022-04-01", "abstract": "The Ontario Ketamine and Infusion Centre (OKIC) is a CPSO-certified Level-II OHP and an outpatient centre for intravenous ketamine treatments for treatment-resistant depression.\u2026", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT07099235", "source": "ClinicalTrials.gov", "first_seen": "2026-08-24", "relevance": { "relevant": true, "reason": "Ketamine treatment for treatment-resistant depression in humans.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-24" } }, { "id": "43b2a2385ec9b58a8c3c465ba3bdb1de5f2e2c205675b271fffd74ba5036f498", "title": "Ketamine & Crisis Response Plan for Suicidal Ideation in the ED", "compound": "ketamine", "type": "phase_2", "institution": "The University of Texas Health Science Center at San Antonio", "condition": "other", "sample_size": 24, "status": "recruiting", "date": "2023-01-06", "abstract": "The goal of this randomized pilot trial is to assess the feasibility of administering a combination of 100mg intramuscular (IM) ketamine and Crisis Response Plan (a short psychosocial intervention) for patients with acute suicidality in the context of the Emergency Department setting.\u2026", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT05696691", "source": "ClinicalTrials.gov", "first_seen": "2026-08-24", "relevance": { "relevant": true, "reason": "Ketamine for suicidal ideation in an emergency department setting.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-24" } }, { "id": "fd2de3a5ff90599f43787fb359a415e088e8adc7885ca9fa1905339b35d5ed3f", "title": "Ketamine As an Adjunctive Therapy for Major Depression (2)", "compound": "ketamine", "type": "phase_3", "institution": "University of Dublin, Trinity College", "condition": "depression", "sample_size": 63, "status": "completed", "date": "2021-09-13", "abstract": "Pragmatic, randomised, controlled, parallel-group, superiority trial of ketamine vs. midazolam as an adjunctive therapy for depression.\u2026", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT04939649", "source": "ClinicalTrials.gov", "first_seen": "2026-08-24", "relevance": { "relevant": true, "reason": "Ketamine for major depression in a human clinical trial.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-24" } }, { "id": "d82bef4b786558a63a070103b72ad13abccfff8b8b0ab78319dbdda5dc8fd5fc", "title": "Ketamine and Lidocaine Infusion in Refractory Chronic Migraine", "compound": "ketamine", "type": "observational", "institution": "Assiut University", "condition": "cluster_headache", "sample_size": 44, "status": "recruiting", "date": "2025-06-01", "abstract": "Ketamine and lidocaine infusion for refractory chronic migraine: Comparative Study", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT06935552", "source": "ClinicalTrials.gov", "first_seen": "2026-08-24", "relevance": { "relevant": true, "reason": "Ketamine for chronic migraine is a relevant therapeutic use.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-24" } }, { "id": "61ee67494bef8b8441c8c2dc394f75adc95e25b5f6d70ac29761021cddf837a9", "title": "Ketamine Assisted Psychotherapy for Treating Comorbid Chronic Pain and PTSD", "compound": "ketamine", "type": "phase_1", "institution": "Queen's University", "condition": "PTSD", "sample_size": 30, "status": "recruiting", "date": "2025-10-01", "abstract": "The goal of this pilot study is to evaluate the feasibility of conducting a clinical trial assessing if ketamine infusions combined to mindfulness therapy works better than psychotherapy alone to treat chronic pain and PTSD in adults living with both conditions.\u2026", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT07009158", "source": "ClinicalTrials.gov", "first_seen": "2026-08-24", "relevance": { "relevant": true, "reason": "Ketamine for comorbid chronic pain and PTSD in humans.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-24" } }, { "id": "b23db14052cb17d925f9b9c3362260aa5fb3118ae1d45a7004e5948592ee11d8", "title": "Subanesthetic Esketamine in Modified ECT for Severe Depression in Adolescents: Clinical and Mechanistic Study", "compound": "ketamine", "type": "observational", "institution": "Min Su", "condition": "depression", "sample_size": 220, "status": "recruiting", "date": "2025-11-25", "abstract": "The study design was a randomized, double blind, parallel controlled trial.The goal of this clinical trial is to learn if esketamine-assisted modified electroconvulsive therapy (ESK-MECT) works to treat severe depression in adolescents. It will also learn about the safety of ESK-MECT.\u2026", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT07247968", "source": "ClinicalTrials.gov", "first_seen": "2026-08-24", "relevance": { "relevant": true, "reason": "Esketamine for severe depression in adolescents.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-24" } }, { "id": "946b9e23f366791e3d30455088215a8eb872de13c1055982ffb8bbd18ef7b32e", "title": "Ketamine and Scopolamine Infusions for Treatment-resistant Major Depressive Disorder", "compound": "ketamine", "type": "observational", "institution": "Massachusetts General Hospital", "condition": "depression", "sample_size": 0, "status": "completed", "date": "2015-09-01", "abstract": "Ketamine infusions resulted in an acute reduction in global depression scores and in severity of suicidal ideation. Scopolamine infusions produced also a significant improvement in depression that was sustained over time.\u2026", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT01613820", "source": "ClinicalTrials.gov", "first_seen": "2026-08-24", "relevance": { "relevant": true, "reason": "Ketamine for treatment-resistant depression.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-24" } }, { "id": "c830a41f9c6338c6824ac583159d231ec770f62235bd1a084b91770752825ca8", "title": "Cognitive Behavioral Therapy Following Esketamine for Major Depression and Suicidal Ideation for Relapse Prevention", "compound": "ketamine", "type": "observational", "institution": "Yale University", "condition": "depression", "sample_size": 92, "status": "completed", "date": "2021-03-05", "abstract": "This is a rater-blinded, randomized controlled trial. All patients will receive esketamine for treatment of Major Depression with Suicidal Ideation (MDSI). Subjects will be randomized (1:1) to receive CBT (computer-assisted) or TAU alone following esketamine.", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT04760652", "source": "ClinicalTrials.gov", "first_seen": "2026-08-24", "relevance": { "relevant": true, "reason": "Esketamine for major depression and suicidal ideation.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-24" } }, { "id": "3eba78fbd632015b632f176fe57630eb732acc97d867428eafeb208f4a8e335d", "title": "i-CBT and IV Ketamine for Suicidality in Treatment-Resistant Depression: A Randomized, Midazolam-Controlled Clinical Trial", "compound": "ketamine", "type": "phase_2", "institution": "University Health Network, Toronto", "condition": "depression", "sample_size": 110, "status": "recruiting", "date": "2024-01-02", "abstract": "Approximately four thousand Canadians die by suicide every year, and suicide is the second leading cause of death in youth and young adults (15-34 years). Most people with depression experience thoughts of suicide and many will also plan and/or attempt suicide at some time in their life.\u2026", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT06480500", "source": "ClinicalTrials.gov", "first_seen": "2026-08-24", "relevance": { "relevant": true, "reason": "IV ketamine for suicidality in treatment-resistant depression.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-24" } }, { "id": "ad938804dbc2953bd7ded7d8fd3a828b46eed741fbb414382c7e9264eba027be", "title": "Ketamine in Borderline Personality Disorder", "compound": "ketamine", "type": "phase_2", "institution": "Yale University", "condition": "other", "sample_size": 22, "status": "completed", "date": "2018-02-15", "abstract": "The purpose of this study is to test the potential of the rapid-acting anti-depressant ketamine to decrease suicidality in Borderline Personality Disorder (BPD). The rate of completed suicide in BPD is similar to that of depression or schizophrenia.\u2026", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT03395314", "source": "ClinicalTrials.gov", "first_seen": "2026-08-24", "relevance": { "relevant": true, "reason": "Ketamine for psychiatric treatment of Borderline Personality Disorder.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-24" } }, { "id": "cb7fb52b552d3d6bed1d12b86e2750349855f6c701fe05aae7688c968e22da18", "title": "IV Ketamine Shows Rapid Benefits for Suicide Risk, Depression in Major Depressive Episodes", "compound": "ketamine", "type": "news", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-05-06", "abstract": "1. Shim SR, Jeong HS, Bommersbach TJ, et al. Ketamine infusions and rapid reduction of suicidal and depressive symptoms in major depressive episode: a systematic review and meta-analysis. _JAMA Psychiatry_. Published online May 6, 2026.\u2026", "outcome_summary": "Intravenous ketamine demonstrated rapid and significant reductions in suicidal ideation and depressive symptoms in patients with major depressive episodes. The treatment was well-tolerated, with adverse events being transient.", "doi": null, "url": "https://www.ajmc.com/view/iv-ketamine-shows-rapid-benefits-for-suicide-risk-depression-in-major-depressive-episodes", "source": "General News", "first_seen": "2026-08-24", "relevance": { "relevant": true, "reason": "IV ketamine for depression and suicidal ideation in humans.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-24" } }, { "id": "70c7654a1498e13fbd637aaf0369598afae03e11d674209fb128a3d98e6e424b", "title": "Structural imaging predictors of ketamine response in treatment-resistant depression: a", "compound": "ketamine", "type": "news", "institution": null, "condition": "depression", "sample_size": null, "status": "other", "date": "2026-05-12", "abstract": "Version of record: 06 July 2026 DOI: ### Share this article Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article.\u2026", "outcome_summary": null, "doi": "s41398-026-04085-4", "url": "https://www.nature.com/articles/s41398-026-04085-4", "source": "General News", "first_seen": "2026-08-24", "relevance": { "relevant": true, "reason": "Predictors of ketamine response in treatment-resistant depression.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-24" } }, { "id": "18a5d176907058f9b6f398b7cae6df11c7295972d19896fcbe53d84ca9369062", "title": "Ketamine: How Yale Redefined Depression Treatment", "compound": "ketamine", "type": "news", "institution": "Yale School of Medicine", "condition": "depression", "sample_size": null, "status": "published", "date": "2026-06-16", "abstract": "The results of studies on esketamine were remarkable. Clinical trials showed that esketamine was effective even for patients who had not responded to multiple prior treatments.\u2026", "outcome_summary": "In 2000, Yale researchers reported that ketamine could rapidly alleviate symptoms of major depression, often within hours, marking a significant advance in treatment and opening new research avenues. Ketamine targets the brain's glutamate system, stimulating the production of new synapses between brain cells, which contrasts with traditional antidepressants that act on serotonin pathways and take weeks to show effect.", "doi": "10.1075/cd.20001.kri", "url": "https://medicine.yale.edu/news-article/ketamine-how-yale-redefined-depression-treatment", "source": "General News", "first_seen": "2026-08-24", "relevance": { "relevant": true, "reason": "Ketamine for depression treatment in humans.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-24" } } ], "dmt": [ { "id": "3db90706157935a5ae7d1b1a9fff22e20c85732359e3e182998a55913262111b", "title": "Advancing Next-Generation Psychedelic Therapeutics through Selective 5\u2011HT2A Activation, Precision Aerosol Delivery, and Optimized 5\u2011MeO-DMT Treatment Paradigms.", "compound": "dmt", "type": "phase_2", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-08-13", "abstract": "The psychedelic therapeutics field continues to evolve beyond classical hallucinogens toward integrated treatment platforms that combine optimized pharmacology, drug delivery, and clinical implementation.\u2026", "outcome_summary": null, "doi": "10.1021/acsmedchemlett.6c00364", "url": "https://pubmed.ncbi.nlm.nih.gov/42621912/", "source": "PubMed", "first_seen": "2026-08-24", "relevance": { "relevant": true, "reason": "Psychedelic therapeutics, 5-HT2A activation, and 5-MeO-DMT treatment paradigms.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-24" } } ], "other": [ { "id": "e1cc5a7a9751695f7a138918971c535aed3f694c68759589e9bf6da4b53ee646", "title": "Long Term Follow Up Study to COMP 001 And COMP 003 Trials (P-TRD LTFU)", "compound": "other", "type": "observational", "institution": "COMPASS Pathways", "condition": "depression", "sample_size": 66, "status": "completed", "date": "2020-07-20", "abstract": "The primary objective of this study is to assess the long-term efficacy of psilocybin with respect to use of new antidepressant treatment, hospitalisations for depression, suicidality, and depressive severity rated using the Montgomery and Asberg Depression Rating Scale (MADRS) over a total of 52 weeks (compared across the 1 mg, 10 mg and 25 mg psilocybin groups from COMP 001).", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT04519957", "source": "ClinicalTrials.gov", "first_seen": "2026-08-24", "relevance": { "relevant": true, "reason": "Long-term follow-up of psilocybin for depression treatment.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-24" } }, { "id": "9829cdb48a2a55e93b9e91118445305258703c63a1f47558391921f03482145b", "title": "Digital Interventions for Adults with Treatment-Resistant Depression: a Pilot Study", "compound": "other", "type": "observational", "institution": "Unity Health Toronto", "condition": "depression", "sample_size": 200, "status": "recruiting", "date": "2024-12-16", "abstract": "The goal of this observational study is to learn about remote mental health monitoring technology for adults with treatment-resistant depression.\u2026", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT06732089", "source": "ClinicalTrials.gov", "first_seen": "2026-08-24", "relevance": { "relevant": true, "reason": "Treatment-resistant depression is a psychiatric indication.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-24" } }, { "id": "d3f50e33f74ab177f9629c7d4ca856501b7acd23f79a03656ccdc3a6cdc4fcd0", "title": "AOC, Other Members of Congress Tout Psychedelic Benefits as Research Amendments Advance", "compound": "other", "type": "news", "institution": "Department of Defense", "condition": "other", "sample_size": null, "status": "other", "date": "2026-08-08", "abstract": "
In this week’s psychedelic policy briefing, investigative journalist Jack Gorsline unpacks a wave of state and federal initiatives aimed at expanding alternative therapies for veterans and those battling addiction.\u2026", "outcome_summary": "Bipartisan lawmakers are leveraging the National Defense Authorization Act to extend military clinical trials for substances like psilocybin and MDMA. The Department of Veterans Affairs is also pushing to expedite treatment research for PTSD. A Louisiana law uses opioid settlement funds for a pilot program targeting substance abuse and treatment-resistant mental health conditions.", "doi": null, "url": "https://www.lucid.news/psychedelic-policy-briefing/", "source": "Lucid News", "first_seen": "2026-08-24", "relevance": { "relevant": true, "reason": "Congressional action and VA research on psychedelics for PTSD and mental health.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-24" } }, { "id": "cb413c57c348685efea41022dfd07b5c34bd100350691319ebc20587294a3472", "title": "How Trump is pushing psychedelics reform through the health agencies", "compound": "other", "type": "news", "institution": null, "condition": "PTSD", "sample_size": null, "status": "other", "date": "2026-04-18", "abstract": "Tools & Trackers CRISPR Tracker Breakthrough Device Tracker Generative AI Tracker Obesity Drug Tracker Events Upcoming Events Summits Community STAT Wunderkinds 2026 Video Advertise STAT Brand Studio What's the word?\u2026", "outcome_summary": "An executive order signed by President Trump aims to accelerate research into psychedelic treatments for mental health conditions, particularly PTSD. The order directs federal agencies to identify and remove barriers to research and clinical trials.", "doi": null, "url": "https://www.statnews.com/2026/04/18/psychedelics-ptsd-mental-health-research-boost-from-trump-executive-order", "source": "General News", "first_seen": "2026-08-24", "relevance": { "relevant": true, "reason": "Trump's executive order on psychedelic reform for mental health.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-24" } }, { "id": "3072eca5fea0744ef5fc1bfac9d3e5844f943b5e5856eac7a691f8d4bf8766f1", "title": "U.S. FDA moves to fast-track psychedelic drugs after Trump order", "compound": "other", "type": "regulatory", "institution": "U.S. FDA", "condition": "other", "sample_size": null, "status": "other", "date": "2026-04-24", "abstract": "Skip to main content Exclusive news, data and analytics for financial market professionals Learn more about Refinitiv Secretary Robert F.Kennedy Jr., Joe Rogan, and Americans for Ibogaine CEO W. Bryan Hubbard, in the Oval Office of the White House in Washington, D.C., April 18, 2026.\u2026", "outcome_summary": "The U.S. Food and Drug Administration (FDA) is moving to fast-track the development of psychedelic drugs for medical use, following an executive order from former President Donald Trump. This initiative aims to accelerate the review process for these novel therapies.", "doi": null, "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-moves-fast-track-psychedelic-drugs-after-trump-order-2026-04-24", "source": "General News", "first_seen": "2026-08-24", "relevance": { "relevant": true, "reason": "FDA fast-tracking psychedelic drugs for medical use", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-24" } } ] } }